SIL 204
Alternative Names: KRASG12D-LODER; siG12D-LODER; SIL-204Latest Information Update: 14 Jul 2025
At a glance
- Originator Silenseed
- Developer Silexion Therapeutics
- Class Antineoplastics; Small interfering RNA
- Mechanism of Action KRAS protein expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Pancreatic cancer
- Preclinical Colorectal cancer; Lung cancer
Most Recent Events
- 09 Jul 2025 Pharmacodynamics data from a preclinical trial in Lung Cancer released by Silexion Therapeutics
- 09 Jul 2025 Silexion Therapeutics plans a phase II/III trial for Pancreatic cancer (Late-stage disease, Adjunctive therapy) in the second quarter of 2026
- 29 May 2025 Pharmacodynamics data from a preclinical trial in Pancreatic cancer, Colorectal cancer, and Lung Cancer released by Silexion Therapeutics